ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PURI Puricore

28.75
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Puricore LSE:PURI London Ordinary Share GB00B3XBCR18 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 28.75 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Realm Therapeutics PLC Conference Presentation

06/03/2017 7:01am

RNS Non-Regulatory


TIDMRLM

Realm Therapeutics PLC

06 March 2017

Realm Therapeutics plc

("Realm Therapeutics", "Realm" or the "Company")

Realm Therapeutics to present at Sachs 10(th) Annual European Life Science CEO Conference

6 March 2017 - Realm Therapeutics plc (AIM: RLM), an emerging specialty biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin, CEO, will be presenting on Tuesday, March 7, 2017, at the Sachs 10(th) Annual European Life Science CEO Forum at the Hilton Zurich Airport Hotel in Zurich, Switzerland.

Mr. Martin will review the Company's two drug development programs - PR022 for Atopic Dermatitis and PR013 for Allergic Conjunctivitis. The Company recently announced that the US Food and Drug Administration (FDA) has permitted Realm's Investigational New Drug (IND) application to proceed into Phase II clinical trials with its lead drug candidate PR022, and is on track to submit an IND for PR013 in Q3.

Enquiries:

 
                                         +44 (0) 20 3727 
 Realm Therapeutics plc                   1000 
 Alex Martin, Chief Executive Officer 
 Marella Thorell, Chief Financial 
  Officer and Chief Operating Officer 
 
                                         +44 (0) 20 3727 
 FTI Consulting                           1000 
 Simon Conway / Mo Noonan 
 
 N+1 Singer (Nominated Adviser and       +44 (0) 20 7496 
  Broker)                                 3000 
 Aubrey Powell / Lauren Kettle 
 

About Realm Therapeutics

Realm Therapeutics is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas including Dermatology and Ophthalmology.

Forward looking statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUVSRRBKAORAR

(END) Dow Jones Newswires

March 06, 2017 02:01 ET (07:01 GMT)

1 Year Puricore Chart

1 Year Puricore Chart

1 Month Puricore Chart

1 Month Puricore Chart

Your Recent History

Delayed Upgrade Clock